Overview

Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia

Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to measure how rapidly pregabalin treatment can relieve pain in patients with post-herpetic neuralgia
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Pregabalin
Criteria
Inclusion Criteria:

- Diagnosis of PHN with pain present for at least three months after the healing of a
Herpes Zoster skin lesion.

- Subjects must have completed the Daily Pain Rating Scale in the electronic diary at
least 4 times during screening and have an average daily pain rating score of greater
than or equl to 4 during the 7 +/- 3 days prior to randomization (Visit 2).

Exclusion Criteria:

- History of neurolytic or neurosurgical therapy for PHN.

- Presence of any severe pain associated with conditions other than PHN that may
confound the assessment or self-evaluation of the pain due to PHN.